Exchange: NASDAQ·Updated 07:59 PM EST
TEM logo

TEM Tempus AI Inc

$54.04
$5.57
(9.34%)
Today
Closed $54.04
$0.96
(1.78%)
After Hours
Reported EarningsNov 2
Mkt Cap$9.86B
Vol7.44M

About TEM

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.
31

Bearish Sentiment

How do you feel about TEM?

GSP
Here are the Final 5 Stocks in My Day Trading Watch List Video for November 18th in About 3 Minutes: $TEM $TTWO $HOOD $PEPG $AI .
2
3
gpaisa
$TEM ok you have my attention now. Relative strength now in the middle markets jocking and jiving sets up next leaders.
1
6
MD109
$TEM There are lots of ongoing conversations within the large AI frontier labs regarding training foundation models for healthcare applications. I am confident they are debating whether to sign significant data licensing deals with Tempus, or to acquire the company to gain a large competitive advantage in healthcare AI. $ANT is particularly interested in training healthcare foundation models and they know Tempus has the best proprietary multimodel data set which would be critical to train their models. When the news hits of $TEM signing deals with $ANT , OpenAI, $GOOG, $MSFT investors will quickly realize that Tempus was intentionally built to become a giant in the burgeoning healthcare AI space. I couldn’t be more bullish on the long term outlook for Tempus.
8
MD109
$TEM I just re-shared my post on Tempus from July 23, 2026. Stock is up 83% since that post a little over 3 months ago. I continue to view $TEM as a very early stage company. I believe they will become one of the largest and most important companies in the Healthcare AI space. As long as they continue to execute, Tempus will remain my largest position for many years. My bullish long-term thesis on Tempus strengthened significantly when they announced their intention to acquire $PSNL.
8
GSP
Here are the Final 2 Stocks in My Day Trading Watch List Video for November 17th in About 3 Minutes: $TEM $TTWO .
1
4
DekmarTrades
TEMPUS AI $TEM Q3’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $411.5M (Est. $409M) 🟢; +23% YoY 🔹 Adj. EPS: $0.07 (Est. -$0.08) 🟢 🔹 Adj. EBITDA: $25.6M Raises FY26 Guide: 🔹 Revenue: $1.60B-$1.61B (Est. $1.59B) 🟢 🔹 Adj. EBITDA: ~$65M Segment Revenue: 🔹 Diagnostics: $303.5M; +20% YoY 🔹 Data & Applications: $108.1M; +33% YoY Announcements: 🔹 FDA: Two 510(k) clearances for ECG-PH and ECG-MR 🔹 Research Platform: 100,000 whole genomes planned Key Updates: 🔹 Data Licensing: >$550M bookings YTD; BMS deals up to $137.5M and $55M 🔹 Personalis acquisition cleared regulatory review Comments: 🔸 “Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in Data & Applications”
7
StocktwitsEarnings
$TEM Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.07 up 163.64% YoY • Reported revenue of $411.54M up 23.14% YoY
6
upsidetrader
$TEM The fundamental story backs the chart: pharma data deals are stacking up, margins are improving, and guidance was raised last quarter. The risk is the calendar. You’d be buying a momentum breakout four trading days before a report where the stock has sold off four straight times, even on beats. One way to play it is a partial position now and adding after Monday’s reaction.
1
3
degeneratetrader23
$TEM the silver lining is that volume has been below average this entire drawdown from the 80s, except today was right at average volume.
4
Johnnyf22
$TEM getting crushed since Wednesday. The trading on this stock makes no sense in terms of its financials.
4
RockyTSTH
$TEM - Stock testing recent highs at $85. swing calls added in the group. looking for calls above $85 for a move towards $90 and $100, SOTERIA Precision Medicine Foundation Partners With Tempus To Provide Personalized, Data-Driven Cancer Treatment Insights, Genomic Sequencing To U.S. Military.
4
shortking
$TEM NO WORRIES! HEALTHCARE IS GOLDEN. 10000 shares and adding more…As I said democrats will win both chambers. TEM is saving lives..
4
bsurve1
$TEM notjing wrong in the earning report..it was superb but still moving slowly upwards..expecting to reach $85 today.. is it too much asking for this earning report?
4
tripplett
Some morning trade ideas from my ORB Grok Bot looking for Opening Range Breakout (ORB) strategies. It identifies candidates, then reads the range from 9:30-35 then looks for a breakout over that range before 10am: Today's pick is $TEM (Tempus AI). It beat Q3 estimates and raised its 2026 revenue guidance. It's up 3.43% pre-market on 11.46% of its average volume, and $SPY is up 0.60%. The pick is pending, and I'll watch for a breakout after 9:35 AM ET. $FOXA and $FLNC came close but didn't qualify. FOXA beat earnings but didn't raise guidance, and FLNC's move came from a CEO and CFO change. The pre-market volume figure came from around 9:17 AM ET, so treat it as a little less certain.
1
1
YourfrenPepe420
$TEM sold before close. Not holding through earnings Nov 2nd, looking for a drop in the low $60. Every earning announcement has been a sell the news event. Let the dust settle..
1
1
MattAI
$TEM if Tempus went up 4x it would still be smaller than Natera, so much more room to run
4
USMC223556
$TEM AMAZING MORE GREAT NEWS TEMPUS AI (TEM): MAJOR EUROPEAN MILESTONE! Tempus AI has received EU IVDR Class C certification for its xR RNA sequencing assay, strengthening its position in cancer diagnostics and expanding its commercial opportunities across Europe. THE REVENUE OPPORTUNITY: European market expansion, increased cancer testing, and additional pharmaceutical partnerships could create significant new revenue opportunities for Tempus. Another important achievement as Tempus AI prepares to report Q3 earnings on November 2!
4
RockyTSTH
$TEM Tempus AI shares are trading higher after the company announced a multi-year agreement with Bristol Myers Squibb, under which BMS will license multimodal oncology data from Tempus through 2031.
4
GTA_Terminal
Most $TEM options money went to calls today (Nov 16), with roughly two-thirds of $8.3M in premium on that side and about 25,000 contracts traded (bullish). The shares were at $65, down 9.6%. One order stood out: 1,700 calls expiring Dec 18 for roughly $222K; largely new positioning. Technicals: lost the 100 EMA; that level is now above the price, around $67. Source: GTA Terminal from Global Traders Academy.
3
MD109
$TEM There is so much hidden value in $TEM that is currently underappreciated, but will eventually generate billions in annual revenue. Take a close look at their apps business and ask yourself what it will look like once all of their AI enabled apps are reimbursed. This is already starting to happen since the health economic benefits of those applications are becoming obvious. Then there is the cancer vaccine business which will bring substantial revenue. Also the MRD business will scale faster and be larger than most realize - rivaling $NTRA. Once CRC gets a positive MolDx approval MRD revenue will explode higher. Lastly, I do expect the large frontier labs to become their largest data customers in the near future. Tempus will have diverse revenue streams which will compound for many years.
1

Advertisement|Remove ads.